HUP0400891A2 - 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds - Google Patents
7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds Download PDFInfo
- Publication number
- HUP0400891A2 HUP0400891A2 HU0400891A HUP0400891A HUP0400891A2 HU P0400891 A2 HUP0400891 A2 HU P0400891A2 HU 0400891 A HU0400891 A HU 0400891A HU P0400891 A HUP0400891 A HU P0400891A HU P0400891 A2 HUP0400891 A2 HU P0400891A2
- Authority
- HU
- Hungary
- Prior art keywords
- general formula
- pyrrolo
- nmr
- ppm
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 230000008569 process Effects 0.000 title claims description 9
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 3
- -1 nitro, amino Chemical group 0.000 claims description 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 14
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 8
- 239000003495 polar organic solvent Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 7
- 150000002429 hydrazines Chemical class 0.000 claims description 7
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 claims description 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- 208000004454 Hyperalgesia Diseases 0.000 claims description 5
- 239000005457 ice water Substances 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000002981 neuropathic effect Effects 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000035154 Hyperesthesia Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 29
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- KTXPBSHZUNNRIG-UHFFFAOYSA-N 2-amino-1-(3-chloroanilino)-4,5-dimethylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C)=C(C)N1NC1=CC=CC(Cl)=C1 KTXPBSHZUNNRIG-UHFFFAOYSA-N 0.000 description 11
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- VVFHRCVJCUDXNI-UHFFFAOYSA-N 4-chloro-7-(3-chlorophenyl)-5,6-dimethylpyrrolo[2,3-d]pyrimidine Chemical compound CC1=C(C)C2=C(Cl)N=CN=C2N1C1=CC=CC(Cl)=C1 VVFHRCVJCUDXNI-UHFFFAOYSA-N 0.000 description 8
- MLDAYAVMTHFOPT-UHFFFAOYSA-N [5,6-dimethyl-7-(3-morpholin-4-ylpropyl)pyrrolo[2,3-d]pyrimidin-4-yl]hydrazine Chemical compound CC1=C(C)C2=C(NN)N=CN=C2N1CCCN1CCOCC1 MLDAYAVMTHFOPT-UHFFFAOYSA-N 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 6
- ZQMSJWJNYLHMAG-UHFFFAOYSA-N 4-[3-(4-chloro-5,6-dimethylpyrrolo[2,3-d]pyrimidin-7-yl)propyl]morpholine Chemical compound CC1=C(C)C2=C(Cl)N=CN=C2N1CCCN1CCOCC1 ZQMSJWJNYLHMAG-UHFFFAOYSA-N 0.000 description 6
- ZSUXKRKJJKNFLV-UHFFFAOYSA-N 7-(3-chloroanilino)-5,6-dimethyl-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound CC1=C(C)C(C(N=CN2)=O)=C2N1NC1=CC=CC(Cl)=C1 ZSUXKRKJJKNFLV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 102400000096 Substance P Human genes 0.000 description 6
- 101800003906 Substance P Proteins 0.000 description 6
- CWCFAVAUWWSGRI-UHFFFAOYSA-N [7-(3-chlorophenyl)-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl]hydrazine Chemical compound CC1=C(C)C2=C(NN)N=CN=C2N1C1=CC=CC(Cl)=C1 CWCFAVAUWWSGRI-UHFFFAOYSA-N 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005638 hydrazono group Chemical group 0.000 description 6
- 230000001272 neurogenic effect Effects 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 description 5
- 206010015866 Extravasation Diseases 0.000 description 5
- 235000017663 capsaicin Nutrition 0.000 description 5
- 229960002504 capsaicin Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000036251 extravasation Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- CHIFTAQVXHNVRW-UHFFFAOYSA-N 1h-indole-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNC2=C1 CHIFTAQVXHNVRW-UHFFFAOYSA-N 0.000 description 4
- DJYHIRUZZHLFMX-UHFFFAOYSA-N 2-amino-4,5-dimethyl-1-(3-morpholin-4-ylpropyl)pyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C)=C(C)N1CCCN1CCOCC1 DJYHIRUZZHLFMX-UHFFFAOYSA-N 0.000 description 4
- LGFQFMDMRZOQTJ-UHFFFAOYSA-N 5,6-dimethyl-7-(3-morpholin-4-ylpropyl)-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound CC1=C(C)C2=C(O)N=CN=C2N1CCCN1CCOCC1 LGFQFMDMRZOQTJ-UHFFFAOYSA-N 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 4
- 229960003699 evans blue Drugs 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 239000008164 mustard oil Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LAICMSHWIXBOHV-UHFFFAOYSA-N 2-amino-1-(3-chlorophenyl)-4,5-dimethylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C)=C(C)N1C1=CC=CC(Cl)=C1 LAICMSHWIXBOHV-UHFFFAOYSA-N 0.000 description 2
- JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 2
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 2
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 2
- YTHJCZRFJGXPTL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1[N+]([O-])=O YTHJCZRFJGXPTL-UHFFFAOYSA-N 0.000 description 2
- FJUBBFVKESGGSK-UHFFFAOYSA-N 5-tert-butyl-2-(3-nitrophenyl)pyrazol-3-amine Chemical compound N1=C(C(C)(C)C)C=C(N)N1C1=CC=CC([N+]([O-])=O)=C1 FJUBBFVKESGGSK-UHFFFAOYSA-N 0.000 description 2
- ISXKAJBUZVKEJP-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidin-4-ylhydrazine Chemical class NNC1=NC=NC2=C1C=CN2 ISXKAJBUZVKEJP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- VHWNARFLVWATEW-UHFFFAOYSA-N (7-benzyl-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl)hydrazine Chemical compound CC1=C(C)C2=C(NN)N=CN=C2N1CC1=CC=CC=C1 VHWNARFLVWATEW-UHFFFAOYSA-N 0.000 description 1
- AOVWJWYVLYFRPC-UHFFFAOYSA-N 1,4-dichloroindole-2,3-dione Chemical compound C1=CC=C(Cl)C2=C1N(Cl)C(=O)C2=O AOVWJWYVLYFRPC-UHFFFAOYSA-N 0.000 description 1
- MYRPBJZXSAHNGO-UHFFFAOYSA-N 1,4-dioxane;ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O.C1COCCO1 MYRPBJZXSAHNGO-UHFFFAOYSA-N 0.000 description 1
- PVRCMHLWQZWNDV-UHFFFAOYSA-N 1-benzyl-2-[[7-(3-chlorophenyl)-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl]amino]-4,5-dimethylpyrrole-3-carbonitrile Chemical compound N=1C=NC=2N(C=3C=C(Cl)C=CC=3)C(C)=C(C)C=2C=1NC1=C(C#N)C(C)=C(C)N1CC1=CC=CC=C1 PVRCMHLWQZWNDV-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- UBHYCFBVIXOJJO-UHFFFAOYSA-N 2,3-dioxo-1h-indole-5-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2NC(=O)C(=O)C2=C1 UBHYCFBVIXOJJO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BDCPAUKUEUZDHQ-UHFFFAOYSA-N 3-[2-(7-benzyl-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl)hydrazinyl]-5-bromoindol-2-one Chemical compound CC1=C(C)C2=C(NNC=3C(N=C4C=CC(Br)=CC4=3)=O)N=CN=C2N1CC1=CC=CC=C1 BDCPAUKUEUZDHQ-UHFFFAOYSA-N 0.000 description 1
- MEPNHDYRUJHPCU-UHFFFAOYSA-N 3-[2-(7-benzyl-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl)hydrazinyl]indol-2-one Chemical compound CC1=C(C)C2=C(NNC=3C(N=C4C=CC=CC4=3)=O)N=CN=C2N1CC1=CC=CC=C1 MEPNHDYRUJHPCU-UHFFFAOYSA-N 0.000 description 1
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 1
- CLBXCDSXUXNOIM-UHFFFAOYSA-N 3-oxidanylbutan-2-one Chemical compound CC(O)C(C)=O.CC(O)C(C)=O CLBXCDSXUXNOIM-UHFFFAOYSA-N 0.000 description 1
- LKCXYJHTXWYXMZ-UHFFFAOYSA-N 4,6-dichloro-3-[2-[5,6-dimethyl-7-(3-morpholin-4-ylpropyl)pyrrolo[2,3-d]pyrimidin-4-yl]hydrazinyl]indol-2-one Chemical compound CC1=C(C)C2=C(NNC=3C(N=C4C=C(Cl)C=C(Cl)C4=3)=O)N=CN=C2N1CCCN1CCOCC1 LKCXYJHTXWYXMZ-UHFFFAOYSA-N 0.000 description 1
- NCHZIPDCUNFBBR-UHFFFAOYSA-N 4-[C-(7-benzyl-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl)carbonohydrazonoyl]-2,6-dimethylphenol Chemical compound C(C1=CC=CC=C1)N1C(=C(C2=C1N=CN=C2C(C1=CC(=C(C(=C1)C)O)C)=NN)C)C NCHZIPDCUNFBBR-UHFFFAOYSA-N 0.000 description 1
- IGOOCJOHSVYDDT-UHFFFAOYSA-N 4-[C-(7-benzyl-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-yl)carbonohydrazonoyl]-2-nitrophenol Chemical compound C(C1=CC=CC=C1)N1C(=C(C2=C1N=CN=C2C(C1=CC(=C(C=C1)O)[N+](=O)[O-])=NN)C)C IGOOCJOHSVYDDT-UHFFFAOYSA-N 0.000 description 1
- XHDJYQWGFIBCEP-UHFFFAOYSA-N 5-Chloro-1H-indole-2,3-dione Chemical compound ClC1=CC=C2NC(=O)C(=O)C2=C1 XHDJYQWGFIBCEP-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- PFLXXPCXGSWEEE-UHFFFAOYSA-N 7-(3-chlorophenyl)-5,6-dimethyl-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound CC1=C(C)C(C(N=CN2)=O)=C2N1C1=CC=CC(Cl)=C1 PFLXXPCXGSWEEE-UHFFFAOYSA-N 0.000 description 1
- XNJFBXOKYCGIBR-UHFFFAOYSA-N 7-benzyl-5,6-dimethyl-n-[[4-(trifluoromethyl)phenyl]methylideneamino]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(CC=3C=CC=CC=3)C(C)=C(C)C2=C1NN=CC1=CC=C(C(F)(F)F)C=C1 XNJFBXOKYCGIBR-UHFFFAOYSA-N 0.000 description 1
- KALLFFTXSZDZDK-UHFFFAOYSA-N 7-benzyl-n-[(2-methoxyphenyl)methylideneamino]-5,6-dimethylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC=C1C=NNC1=NC=NC2=C1C(C)=C(C)N2CC1=CC=CC=C1 KALLFFTXSZDZDK-UHFFFAOYSA-N 0.000 description 1
- MPLXQMMMGDYXIT-UHFFFAOYSA-N 7-chloro-1h-indole-2,3-dione Chemical compound ClC1=CC=CC2=C1NC(=O)C2=O MPLXQMMMGDYXIT-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- UEQRXKMZIHHBNH-UHFFFAOYSA-N ClC=1C=C(C=CC1)N1C(=C(C2=C1N=CN=C2C(C=2C=C(C(=CC2)O)O)=NN)C)C Chemical compound ClC=1C=C(C=CC1)N1C(=C(C2=C1N=CN=C2C(C=2C=C(C(=CC2)O)O)=NN)C)C UEQRXKMZIHHBNH-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- HMZZEIRBCZROPF-UHFFFAOYSA-N n-[5-tert-butyl-2-(3-nitrophenyl)pyrazol-3-yl]-5,6-dimethyl-7-(3-morpholin-4-ylpropyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=CN=C2N(CCCN3CCOCC3)C(C)=C(C)C2=C1NC1=CC(C(C)(C)C)=NN1C1=CC=CC([N+]([O-])=O)=C1 HMZZEIRBCZROPF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N o-dihydroxy-benzene Natural products OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0400891A HUP0400891A2 (en) | 2004-04-29 | 2004-04-29 | 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds |
| PCT/HU2005/000040 WO2005105804A1 (en) | 2004-04-29 | 2005-04-25 | 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT |
| CNA2005800206893A CN1972946A (zh) | 2004-04-29 | 2005-04-25 | 7H－吡咯并[2,3－d]嘧啶衍生物及其治疗可接受的盐、含有它们的药物制剂和制备该活性物质的方法 |
| KR1020067025009A KR20070047737A (ko) | 2004-04-29 | 2005-04-25 | 7Ｈ-피롤로[2,3-ｄ]피리미딘뿐만 아니라 이들의 치료적으로허용되는 염, 이들을 함유하는 약제학적 제제 및 활성제의제조방법 |
| CA002564277A CA2564277A1 (en) | 2004-04-29 | 2005-04-25 | 7h-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent |
| AT05739554T ATE462706T1 (de) | 2004-04-29 | 2005-04-25 | 7h-pyrroloä2,3-düpyrimidinderivate sowie deren therapeutisch annehmbare salze, pharmazeutische zubereitungen, die diese enthalten, und verfahren zur herstellung des wirkstoffs |
| JP2007510131A JP2007534737A (ja) | 2004-04-29 | 2005-04-25 | ７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、ならびにその治療的に許容される塩、それらを含有する製薬調製物および活性剤を生成するプロセス |
| US11/587,851 US20080214583A1 (en) | 2004-04-29 | 2005-04-25 | 7H-Pyrrolo[2,3-D]Pyrimidine Derivatives, As Well As Their Therapeutically Acceptable Salts, Pharmaceutical Preparations Containing Them And Process For Production The Active Agent |
| AU2005238287A AU2005238287A1 (en) | 2004-04-29 | 2005-04-25 | 7H-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent |
| DE602005020281T DE602005020281D1 (de) | 2004-04-29 | 2005-04-25 | 7H-PYRROLOÄ2,3-dÜPYRIMIDINDERIVATE SOWIE DEREN THERAPEUTISCH ANNEHMBARE SALZE, PHARMAZEUTISCHE ZUBEREITUNGEN, DIE DIESE ENTHALTEN, UND VERFAHREN ZUR HERSTELLUNG DES WIRKSTOFFS |
| EP05739554A EP1756110B1 (en) | 2004-04-29 | 2005-04-25 | 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT |
| RU2006141393/04A RU2391344C2 (ru) | 2004-04-29 | 2005-04-25 | ПРОИЗВОДНЫЕ 7Н-ПИРРОЛ[2,3-d]ПИРИМИДИНА, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| IL178906A IL178906A0 (en) | 2004-04-29 | 2006-10-26 | 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR PRODUCTION THE ACTIVE AGENT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0400891A HUP0400891A2 (en) | 2004-04-29 | 2004-04-29 | 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU0400891D0 HU0400891D0 (en) | 2004-07-28 |
| HUP0400891A2 true HUP0400891A2 (en) | 2006-04-28 |
Family
ID=89982174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400891A HUP0400891A2 (en) | 2004-04-29 | 2004-04-29 | 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080214583A1 (enExample) |
| EP (1) | EP1756110B1 (enExample) |
| JP (1) | JP2007534737A (enExample) |
| KR (1) | KR20070047737A (enExample) |
| CN (1) | CN1972946A (enExample) |
| AT (1) | ATE462706T1 (enExample) |
| AU (1) | AU2005238287A1 (enExample) |
| CA (1) | CA2564277A1 (enExample) |
| DE (1) | DE602005020281D1 (enExample) |
| HU (1) | HUP0400891A2 (enExample) |
| IL (1) | IL178906A0 (enExample) |
| RU (1) | RU2391344C2 (enExample) |
| WO (1) | WO2005105804A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873971A1 (en) * | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
| WO2014145576A2 (en) * | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| EP3194399B1 (en) | 2014-09-17 | 2019-04-10 | Pécsi Tudományegyetem | New agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders |
| RU2603770C2 (ru) * | 2014-11-28 | 2016-11-27 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Замещенные пиразинопиримидиноны как блокаторы trpa1 каналов, фармацевтическая композиция, способы их получения и применения |
| CN110483526B (zh) * | 2019-09-09 | 2021-10-01 | 辽宁大学 | 含芳基腙结构的吡唑并[1,5-a]嘧啶类衍生物及其应用 |
| CN119613409A (zh) * | 2024-12-05 | 2025-03-14 | 浙江工业大学 | 吡咯并[2,3-d]嘧啶衍生物及其在制备抗炎药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2818676A1 (de) * | 1978-04-27 | 1979-11-08 | Troponwerke Gmbh & Co Kg | Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO1999059998A1 (en) * | 1998-05-19 | 1999-11-25 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
| RU2001111033A (ru) * | 1998-09-18 | 2003-05-20 | Басф Акциенгезелльшафт (De) | Пирролопиримидины в качестве ингибиторов протеинкиназ |
| CN1195755C (zh) * | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3－d]嘧啶化合物 |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
-
2004
- 2004-04-29 HU HU0400891A patent/HUP0400891A2/hu unknown
-
2005
- 2005-04-25 WO PCT/HU2005/000040 patent/WO2005105804A1/en not_active Ceased
- 2005-04-25 KR KR1020067025009A patent/KR20070047737A/ko not_active Ceased
- 2005-04-25 JP JP2007510131A patent/JP2007534737A/ja not_active Withdrawn
- 2005-04-25 EP EP05739554A patent/EP1756110B1/en not_active Expired - Lifetime
- 2005-04-25 DE DE602005020281T patent/DE602005020281D1/de not_active Expired - Fee Related
- 2005-04-25 AU AU2005238287A patent/AU2005238287A1/en not_active Abandoned
- 2005-04-25 AT AT05739554T patent/ATE462706T1/de not_active IP Right Cessation
- 2005-04-25 US US11/587,851 patent/US20080214583A1/en not_active Abandoned
- 2005-04-25 CA CA002564277A patent/CA2564277A1/en not_active Abandoned
- 2005-04-25 CN CNA2005800206893A patent/CN1972946A/zh active Pending
- 2005-04-25 RU RU2006141393/04A patent/RU2391344C2/ru not_active IP Right Cessation
-
2006
- 2006-10-26 IL IL178906A patent/IL178906A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006141393A (ru) | 2008-06-10 |
| CN1972946A (zh) | 2007-05-30 |
| WO2005105804A1 (en) | 2005-11-10 |
| CA2564277A1 (en) | 2005-11-10 |
| EP1756110B1 (en) | 2010-03-31 |
| DE602005020281D1 (de) | 2010-05-12 |
| RU2391344C2 (ru) | 2010-06-10 |
| EP1756110A1 (en) | 2007-02-28 |
| JP2007534737A (ja) | 2007-11-29 |
| US20080214583A1 (en) | 2008-09-04 |
| HU0400891D0 (en) | 2004-07-28 |
| IL178906A0 (en) | 2007-03-08 |
| AU2005238287A1 (en) | 2005-11-10 |
| ATE462706T1 (de) | 2010-04-15 |
| KR20070047737A (ko) | 2007-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1641805B1 (en) | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | |
| US8012991B2 (en) | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | |
| CA2388658A1 (en) | 1-amino triazolo[4,3-a]quinazolin-5-ones and or -5-thiones inhibiting phosphodiesterase iv | |
| EP2331546B1 (fr) | Derives de 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine, leur preparation et leur application en therapeutique | |
| CA2799926A1 (en) | Heterocyclic compounds as janus kinase inhibitors | |
| Cignarella et al. | Synthesis and biological evaluation of substituted benzo [H] cinnolinones and 3H-benzo [6, 7] cyclohepta [1, 2-c] pyridazinones: Higher homologs of the antihypertensive and antithrombotic 5H-indeno [1, 2-c] pyridazinones | |
| Fayed et al. | Synthesis and anti-inflammatory activity of some new pyrimidinothienocinnoline derivatives | |
| Von der Saal et al. | Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles | |
| HUP0400891A2 (en) | 7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds | |
| PL204650B1 (pl) | 7-(1,1-Dimetyloetylo)-6-(2-etylo-2H-1,2,4-triazol-3-ilometoksy)-3-(2-fluoro-fenylo)-1,2,4-triazolo[4,3,-b]pirydazyna, jej polimorf A, jej zastosowanie, zawierająca ją kompozycja farmaceutyczna i sposób jej wytwarzania | |
| CN107235906A (zh) | 一组吡唑酰胺类衍生物及其应用 | |
| CA2532437C (en) | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | |
| Blankley et al. | Antihypertensive activity of 6-arylpyrido [2, 3-d] pyrimidin-7-amine derivatives. 2. 7-Acyl amide analogs | |
| Dotzauer et al. | 2, 4-Diamino-9H-pyrimido [4, 5-b] indol-5-ols: Synthesis, in vitro cytotoxic activity, and QSAR investigations | |
| CN105503745B (zh) | 含4-氧代喹唑啉-2-基的查耳酮类似物及其制备方法和用途 | |
| HK1106235A (en) | 7h-pyrrolo[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts, pharmaceutical preparations containing them and process for production the active agent | |
| CN101321762A (zh) | 三环内酰胺衍生物、它们的制备和作为药剂的应用 | |
| El-Feky et al. | Synthesis of novel fused pyrimidines and imidazoles as potential analgesics from 2-amino-4-substituted-striazino [1, 2-a] benzimidazoles | |
| CZ314097A3 (cs) | Deriváty 5H,10H-imidazo/1,2-a/indeno/1,2-e/pyrazin-4-onu, způsob jejich přípravy a léčiva, která je obsahují | |
| HK1083844B (en) | N- [3-(3-substituted-pyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-sulfonamides, and compositions, and methods related thereto | |
| JPH01228991A (ja) | 気管支拡張剤としての置換１，２，４−トリアゾロ〔１，５−ａ〕トリアジン | |
| HK1074446B (en) | 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): VARNAI ANIKO, INTERINNO SZABADALMI IRODA, HU Representative=s name: KERENY JUDIT, DANUBIA SZABADALMI ES JOGI IRODA, HU |